Cambridge, MA, United States of America

Roman A Valiulin

This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Alkermes, Inc., Alkermes Pharma Ireland Limited. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roman A Valiulin. Retrieved from https://idiyas.com/inventor/roman-a-valiulin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 9 

% Patents Active = 66.7

 

 

Average Co-Inventor Count = 12.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2020-2026

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Journey of Roman A Valiulin

Introduction: Roman A Valiulin is a distinguished inventor based in Cambridge, MA, known for his groundbreaking contributions to various fields.

Latest Patents: Roman A Valiulin holds several patents in the areas of technology and engineering, showcasing his continuous commitment to innovation.

Career Highlights: With a career spanning over two decades, Valiulin has worked on numerous projects that have revolutionized industries, demonstrating his expertise and passion for creating impactful solutions.

Collaborations: Throughout his career, Roman A Valiulin has collaborated with leading researchers, engineers, and companies, fostering a culture of innovation and excellence in all his endeavors.

Conclusion: Roman A Valiulin's dedication to pushing the boundaries of what is possible through his inventive spirit and collaborative efforts solidifies his position as a prominent figure in the world of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…